Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Titel:
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Auteur:
Tabernero, Josep Hoff, Paulo M. Shen, Lin Ohtsu, Atsushi Shah, Manish A. Siddiqui, Asna Heeson, Sarah Kiermaier, Astrid Macharia, Harrison Restuccia, Eleonora Kang, Yoon-Koo